바이오스펙테이터

바이오스펙테이터 Jongwon Jang 기자

GenBody, one of the largest diagnostic companies in Korea, said on December 20 that it has won a first USD 57 million deal (approximately 62.0 billion KRW) to export Zika virus test kit to a state-run Brazilian company, BahiaFarma.

Following the first shipment, the company plans to ship the second and third Zika test kits of the same volume next year (June–August, November–December).

GenBody said that its sales will break the 100 billion KRW level, while posting an operating income of 50 billion KRW, thanks to the strong export performance of the Zika virus test kit. According to the GenBody officials, its listing on a local stock market will be made available in the first half of 2018.

"On top of the Zika virus test kit, we have first developed a new test kit for the detection of yellow fever virus (YFV) this year. Now that we have acquired ANVISA certification (medical device registration and approval) of the YFV kit, we can qualify for Brazilian export. Thus, we are separately negotiating with BahiaFarma over the export volume of the YFV kit", said GenBody officials.